The molecular landscape of colitis-associated carcinogenesis by Saraggi, Deborah et al.
Original Citation:
The molecular landscape of colitis-associated carcinogenesis
Elsevier B.V.
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3218452 since: 2017-02-06T15:38:10Z
10.1016/j.dld.2016.12.011
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
YA
T
D
A
a
b
c
d
e
a
A
R
A
A
K
B
C
D
I
M
1
s
A
c
n
[
c
g
s
w
g
v
h
1ARTICLE IN PRESSG ModelDLD-3315; No. of Pages 5
Digestive and Liver Disease xxx (2016) xxx–xxx
Contents lists available at ScienceDirect
Digestive  and  Liver  Disease
journa l homepage: www.e lsev ier .com/ locate /d ld
limentary  Tract
he  molecular  landscape  of  colitis-associated  carcinogenesis
eborah  Saraggia,1,  Matteo  Fassana,1,  Claudia  Mescoli e, Marco  Scarpab,  Nicola  Valeri c,d,
ndrea  Michielane, Renata  D’Incáe, Massimo  Ruggea,∗
Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy
Istituto Oncologico Veneto, IOV-IRCCS, Surgical Oncology Unit, Padua, Italy
Department of Molecular Pathology, The Institute of Cancer Research, London, UK
Department of Medicine, The Royal Marsden NHS Trust, London, UK
Department of Surgical Oncology and Gastroenterology (DiSCOG), Gastroenterology Unit, University of Padua, Padua, Italy
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 17 November 2016
ccepted 9 December 2016
vailable online xxx
eywords:
iomarkers
olitis
ysplasia
BD
olecular pathology
a  b  s  t  r  a  c  t
In spite  of the  well-established  histopathological  phenotyping  of  IBD-associated  preneoplastic  and neo-
plastic  lesions,  their  molecular  landscape  remains  to  be fully  elucidated.  Several  studies  have  pinpointed
the initiating  role  of longstanding/relapsing  inﬂammatory  insult  on  the intestinal  mucosa,  with  the  acti-
vation  of  different  pro-inﬂammatory  cytokines  (TNF-,  IL-6, IL-10,  IFN-),  chemokines  and  metabolites
of  arachidonic  acid resulting  in the activation  of key  transcription  factors  such  as NF-B.  Longstand-
ing  inﬂammation  may  also modify  the  intestinal  microbiota,  prompting  the  overgrowth  of  genotoxic
microorganisms,  which  may  act as  further  cancer  promoters.  Most of  the molecular  dysregulation  occur-
ring  in  sporadic  colorectal  carcinogenesis  is  documented  in  colitis-associated  adenocarcinoma  too,  but
marked  differences  have  been  established  in both  their  timing  and prevalence.  Unlike  sporadic  cancers,
TP53  alterations  occur  early  in  IBD-related  carcinogenesis,  while  APC dysregulation  emerges  mainly  in
the most  advanced  stages  of the  oncogenic  cascade.  From  the  therapeutic  standpoint,  colitis-associated
cancers  are  associated  with  a lower  prevalence  of  KRAS  mutations  than  the sporadic  variant.  Epige-
netic  changes,  including  DNA  methylation,  histone  modiﬁcations,  chromatin  remodeling,  and  non-coding
RNAs,  are  signiﬁcantly  involved  in colitis-associated  cancer  development  and  progression.  The  focus  now
is on  identifying  diagnostic  and  prognostic  biomarkers,  with  a  view  to ultimately  designing  patient-
 Gast
tailored  therapies.
©  2016  Editrice
. Introduction
Sporadic colorectal carcinogenesis comprises a well-established
equence of phenotypic changes and molecular derangements [1].
mong non-syndromic colorectal cancers (CRC), on the other hand,
olitis-associated cancer (CAC) is a particular entity with its own
atural history, precancerous phenotypes, and molecular proﬁle
2].
In both Crohn’s disease (CD) and ulcerative colitis (UC), the
umulative risk of cancer ranges between 3% and 5% [3–5]. In sin-
le patients, the CAC risk increases along with the duration andPlease cite this article in press as: Saraggi D, et al. The molecular lan
http://dx.doi.org/10.1016/j.dld.2016.12.011
everity of the inﬂammatory disease, and rises further in patients
ith familial CRC and/or concomitant primary sclerosing cholan-
itis [6–13].
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The natural history of CAC prompts the recommendation for
follow-up strategies that are consistently based on endoscopic
surveillance coupled with appropriate (extensive) biopsy sampling
[14,15]. The histological detection of precancerous lesions (i.e. dys-
plasia [synonym: intra-epithelial neoplasia; IEN]) is discriminatory
in the choice of clinical strategy for the purpose of secondary cancer
prevention [16,17]. Colitis-associated dysplasia frequently occurs
in the form of patchy, ﬂat lesions that may easily be overlooked,
even with latest-generation high-deﬁnition endoscopy [2,18].
This clinical background means that priority goes to efforts to
identify reliable biomarkers of a high cancer risk and/or early neo-
plastic transformation [19,20]. Such efforts come up against three
main difﬁculties, however: (i) the complexity of the genetic back-
ground behind IBD-associated carcinogenesis; (ii) the confounding
interference of the gut microbiota in colitis-associated carcino-
genesis; and (iii) the characteristics of biopsy samples availabledscape of colitis-associated carcinogenesis. Dig Liver Dis (2016),
for translational research purposes. In clinical practice, IBD biopsy
samples are obtained mainly for diagnostic purposes, and tend
to consist of formalin-ﬁxed, parafﬁn-embedded (FFPE) specimens,
 rights reserved.
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hich are considered sub-optimal for use in downstream molecu-
ar biology procedures [1].
This review aims to provide an up-to-date overview of the
eculiar histology and molecular background of IBD-associated car-
inogenesis.
. Histology of dysplasia and colitis-associated cancer
In IBD patients, dysplasia is the most reliable marker of a
igher risk of malignancy [2,21–23]. The accuracy of the endoscopic
nspection and the appropriateness of the biopsy sampling protocol
oth signiﬁcantly affect the likelihood of dysplasia being detected
istologically, which also depends on the pathologist’s experience
24–27].
Grossly, IBD-associated dysplasia may  occur as ﬂat or raised
polypoid) mucosal lesions [23,28–30]. While the latter are
enerally detectable on “traditional” endoscopy, the reliable assess-
ent of ﬂat lesions demands elective endoscopy experience and
igh-performance instruments. Even if such conditions are met,
BD-associated dysplasia is most frequently encountered in ran-
omly obtained biopsy samples [2].
Depending on their histological phenotype, polypoid alterations
an be divided into two sub-categories: (i) dysplasia-associated
esions or masses (DALM); and (ii) adenoma-like lesions [23].
he deﬁnition of DALM includes irregular bumps, plaques, vel-
ety patches, nodules, wart-like thickenings, stricturing lesions and
road-based masses. These lesions can easily be masked by gross
nﬂammatory abnormalities, and they are not usually amenable
o removal using routine endoscopic methods [14,15]. On the
ther hand, adenoma-like lesions (both sessile, and pedunculated)
re endoscopically indistinguishable from sporadic colorectal can-
er, and are easy to remove endoscopically [2,31]. The distinction
etween DALM and adenoma-like dysplasia has far from negligible
linical consequences because polypoid lesions only require endo-
copic resection, whereas the frequent concomitance of DALM with
ancer warrants prophylactic proctocolectomy [27].
As for the histological assessment, the ECCO/ESP Consensus
anel recommends that histological diagnoses be conﬁrmed by
 “GI-dedicated” pathologist [27]. Despite its well-established
eﬁnition, the histological recognition and grading of dysplasia
n this setting suffers from a signiﬁcant inter-observer variabil-
ty. Distinguishing between low-grade (LG) and high-grade (HG)
esions entails a different patient management due to the different
revalence of synchronous cancers detected in dysplasia patients
ndergoing proctocolectomy (LG and HG dysplasia are associated
ith synchronous cancer in 3% and 29% of cases, respectively) [32].
Invasive adenocarcinoma is identiﬁed from the “invasive”
preading of neoplastic cells beyond the native structure of the
olonic glands. Compared with sporadic CRCs, IBD-associated
ancers tend to be multifocal, more often mucinous, frequently
ncluding a signet ring cell component, and featuring a higher his-
ological grade (Fig. 1) [18,29,33].
. Molecular landscapes of colitis-associated cancers
.1. The pathogenic role of the inﬂammatory insult
Colitis-related carcinogenesis is characterized by a cascade of
olecular and phenotypic alterations initiated and sustained by
relapsing) inﬂammation [34,35]. As in other inﬂammation-relatedPlease cite this article in press as: Saraggi D, et al. The molecular lan
http://dx.doi.org/10.1016/j.dld.2016.12.011
arcinogenic models, so too in the IBD setting, the pathogenic role
f longstanding inﬂammation is supported by two main clinical fac-
ors: (i) the risk of CAC increases along with the duration/severity
f the disease; and (ii) the introduction of anti-inﬂammatory PRESS
r Disease xxx (2016) xxx–xxx
treatment is associated with signiﬁcant reduction in this cancer
risk [25,36–38].
The molecular mechanisms linking longstanding IBD with can-
cer are gradually becoming less obscure. The long-term persistence
of inﬂammation sustained by granulocytes, plasma cells, lympho-
cytes, and macrophages results in high levels of pro-inﬂammatory
cytokines (tumor necrosis factor-alpha [TNF-],  interleukin-6 [IL-
6], interleukin-10 [IL-10], interferon-gamma [IFN-]), chemokines
and metabolites of arachidonic acid [39]. This “inﬂammatory back-
ground” leads to the activation of key transcription factors, such
as nuclear transcription factor kappaB [NF-B], that play a pivotal
part in cancer development [29].
Among the pro-inﬂammatory cytokines, IL-6 in particular
promotes proliferation and inhibits apoptosis by activating the
JAK/STAT signaling pathway [40,41]. The IL-6-dependent enhance-
ment of human colon cancer cell proliferation in vitro is largely
mediated by hyperphosphorylation of the transcription factor
STAT3 [42,43]. In biopsy samples obtained from active UC coex-
isting with neoplastic lesions, IL-6 and STAT3 expression in the gut
epithelia is signiﬁcantly higher than in either patients with inac-
tive IBD or non-IBD controls [44]. Matsumoto et al. demonstrated
that activation of the IL-6/STAT3 pathway is involved in both the
experimental development of ileitis (SAMP1/Yit mice) and in can-
cer promotion [45].
In IBD, as in other carcinogenic models, several pro-
inﬂammatory cytokines (particularly IL-1 and TNF-) also
signiﬁcantly enhance the production of cyclo-oxygenase-2 (COX2),
an inducible enzyme that interferes with cell proliferation, angio-
genesis, and apoptosis. In the IBD setting, COX2 mRNA levels have
been found increased in the inﬂamed mucosa, in dysplastic lesions,
and in IBD-associated cancer [46].
Another important mechanism involved in the initiation and/or
progression of CAC is oxidative stress of the colon mucosa due to the
production and accumulation of reactive oxygen species (ROS), and
reactive nitrogen intermediates (RNI) [47]. Stimulated by the pro-
inﬂammatory cytokines, the inﬂammatory cells produce ROS and
RNI, which in turn recruit additional inﬂammatory cells, generating
to a self-promoting pathogenic loop. Oxidative stress is known to be
involved in cancer biology because of its ability to damage DNA, and
cell lipids and proteins [48,49]. For instance, the lipid peroxidation
occurring when ROS and RNI interact with cell membranes gives
rise to DNA adducts that frequently involve the TP53 gene [48,49].
3.2. The intestinal microbiota in the carcinogenic cascade
Mounting evidence supports a role for both intestinal micro-
biota, and innate immune responses in initiating and maintaining
colonic mucosa inﬂammation, and in eventually promoting colon
cancer [29].
Gut microbiota imbalance (i.e. dysbiosis) is well documented
in IBD patients, and dysbiosis is emerging as a key player in the
pathogenesis of CAC. A higher prevalence of colon cancers has been
documented in rodents colonized with feces obtained from CAC
mice than in rodents treated with feces obtained from healthy mice.
The demonstration that neither IL-10-deﬁcient mice, nor TCR/p53
double knockout mice ever develop colon cancer under germfree
environmental conditions further supports the interplay between
colorectal cancer and gut microbiota [50].
IL-10 is a potent anti-inﬂammatory cytokine that inhibits NF-B
signaling [51–53]. IL-10-deﬁcient mice have less diversity in their
intestinal bacteria (a situation consistently demonstrated in bothdscape of colitis-associated carcinogenesis. Dig Liver Dis (2016),
human and experimental cancers). In this murine model, gut colo-
nization with either Escherichia coli or Enterococcus faecalis results
in colonic inﬂammation, but it is noteworthy that only animal colo-
nized by E. coli develop inﬂammation-related colon tumors [54,55].
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[Fig. 1. Pathological and molecular feature
.3. Molecular pathways driving cancer initiation
The major molecular dysregulations involved in sporadic CRCs
ave been documented in colitis-associated neoplastic lesions too,
hough the timing and frequency of such molecular alterations in
he latter reveal features peculiar to IBD [1]. In CAC, as in sporadic
RC, chromosomal instability (CIN), microsatellite instability (MSI),
elomere shortening, and CpG island methylator phenotype (CIMP)
re the main causative events behind genetic instability [29,56]. In
C patients, telomere shortening has been documented in mucosa
djacent to dysplasia and cancer, and it has been detected more
requently in patients who subsequently develop cancer [57,58].
In contrast with the late involvement of TP53 dysregulation in
poradic colon carcinogenesis, seminal mutational proﬁling and
OH studies addressing IBD-associated oncogenesis have consis-
ently pinpointed TP53 mutations and TP53 gene locus loss as early
olecular changes already underway in intraepithelial neoplas-
ic lesions [59–65]. TP53 mutations have also been observed in
on-dysplastic UC-affected mucosa, further supporting the early
nvolvement of TP53 [66]. It is worth adding that mice harboring aPlease cite this article in press as: Saraggi D, et al. The molecular lan
http://dx.doi.org/10.1016/j.dld.2016.12.011
ermline TP53 mutation show a prolonged NF-B activation and a
apid onset of ﬂat dysplastic lesions that progress to invasive car-
inoma in the dextran sulfate sodium (DSS) cancerization model
67].D-related and sporadic adenocarcinomas.
The adenomatous polyposis coli (APC) gene is a driver of sporadic
colorectal carcinogenesis, being involved in -catenin regulation,
cytoskeleton organization, apoptosis, and cell adhesion [1,68]. APC
dysregulation is less frequent in IBD-related carcinogenesis, occur-
ring only in advanced phases (if ever), and it has never been
associated with non-dysplastic mucosa [63,69–71]. In the setting
of IBD, it has been suggested that an enhanced -catenin signal-
ing could be promoted by the inﬂammatory micro-environment
instead.
KRAS mutations are relatively less common in CAC than in
sporadic carcinomas, and this may  have therapeutic implications
[72,73]. A recent whole-exome sequencing study on 31 IBD-related
CRCs demonstrated a low KRAS mutation rate, further validating
both the low prevalence of APC mutations and the high rate of TP53
mutations [74]. The authors also demonstrated that alterations in
SOX9 and EP300 (Wnt pathway), NRG1 (ERBB pathway) and IL16
(cytokine) genes are frequently involved. Their analysis identiﬁed
recurrent mutations in the Rho and Rac GTPase network, pointing
to a role for non-canonical Wnt  signaling in the IBD setting.dscape of colitis-associated carcinogenesis. Dig Liver Dis (2016),
3.4. Epigenetic modiﬁcations
Epigenetic changes – including DNA methylation, histone mod-
iﬁcations, chromatin remodeling and small non-coding microRNAs
 ING ModelY
4 d Live
–
[
p
C
q
s
t
s
r
b
t
s
b
[
s
d
i
m
s
t
i
p
a
4
o
o
y
p
t
v
s
b
b
(
S
c
C
N
F
c
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[ARTICLEDLD-3315; No. of Pages 5
 D. Saraggi et al. / Digestive an
 are involved in both the CRC’s initiation and the progression
75–78]. Epigenetic silencing in DNA repair genes (such as hMLH1,
16INK4a and MGMT), which results in MSI, has been found in the
AC setting too [79]. MLH1 promoter hypermethylation is less fre-
uent than in sporadic MSI  cancers, however, because oxidative
tress and ROS might cause MSI  even in the absence of defects in
he DNA mismatch repair pathway [29]. The CIMP pathway is also
een less often in CAC [80,81].
For the last three decades, microRNAs (miRNAs) have rep-
esented the most promising class of diagnostic and prognostic
iomarkers. Their stability in biological samples, small size, ability
o regulate hundreds of messenger RNAs (mRNAs), and relatively
mall total number (compared to mRNAs) make miRNAs plausi-
le candidates for monitoring the cancer risk associated with IBD
82–84].
In 2008, a seminal study on miRNA expression in colonic mucosa
amples from IBD patients identiﬁed a set of 11 miRNAs expressed
ifferently in active UC vis-à-vis normal colonic mucosa [85]. This
nitial evidence was supported by further studies. Among others,
iR-21 and miR-135b emerged as common key oncogenes in both
poradic and IBD-related carcinogenic processes [86,87]. Moreover,
hanks to their intrinsic stability in body ﬂuids, measuring circulat-
ng miRNA levels in the plasma and serum of IBD patients has shown
otential as a tool for enabling an earlier diagnosis and prognosis,
nd for predicting response to therapy [83,88,89].
. Conclusions
In spite of our thorough understanding of the phenotypic events
ccurring in IBD-related carcinogenesis, its molecular proﬁling has
nly been partially clariﬁed. No reliable biomarkers are available as
et for prognosticating the cancer risk associated with colitis. The
icture is further complicated by the recent acknowledgment of
he inﬂuence of intestinal dysbiosis, which represents an additional
ariable in an already puzzling landscape.
There is growing evidence to support the reliability of some IBD-
peciﬁc molecular markers of cancer risk, but none of them have
een validated as yet, and their therapeutic implications (if any) are
y no means well established. So is it time to test the reliability of
at least) some of these biomarkers in clinical diagnostic practice?
ome of the available evidence seems to suggest that the time has
ome.
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